Pregnancy rates, LH and progesterone concentrations in mares treated with a GnRH agonist.
The aim of the study was to investigate the effect of the GnRH agonist Buserelin given on day 10 after ovulation on pregnancy rate and concentrations of progesterone and LH. Altogether 191 warmblood mares were used for two trials. Fresh or frozen/thawed semen from 27 stallions was used for A.I. In trial A 171 mares received either Buserelin (Receptal, Hoechst, Germany, 40 microg/animal) or 10 ml 0.9% NaCl (placebo). On day 16 after A.I. pregnancy diagnosis was performed by ultrasound scanning of the uterus. For statistical analysis, data were analyzed by a mixed model, with four fixed factors (treatment, type of spermatozoa, A.I. number, reproductive status of the mare) and a random factor (stallion). Least Square Means (LSM) for pregnancy rate were 46.0% in GnRH agonist treated mares and 36.4% in the control group (P=0.22). In trial B 20 lactating and cycling mares were used for endocrine studies. Blood samples were recovered for analyses of progesterone and LH from days 0 to 11. The mean progesterone concentrations increased continuously from days 0 to 8 after ovulation in both groups (GnRH group: from 0.81+/-0.48 to 5.47+/-0.48 ng/ml, control group: from 0.63+/-0.68 to 5.83+/-0.68 ng/ml). Moreover, the progesterone concentrations from days 9 to 11 were not different between the GnRH and the control group. In contrast to this LH concentrations were markedly influenced by the GnRH agonist. On day 10 LH concentrations were significantly higher in GnRH agonist treated than in placebo treated animals. From the data obtained from individual animals it can be concluded that GnRH agonist, given during luteal phase may have different effect on luteal function.
Kanitz
W
W
Research Institute for the Biology of Farm Animals (FBN), Department of Reproductive Biology, Wilhelm-Stahl-Allee 2, D-18196 Dummerstorf, Germany. wkanitz@fbn-dummerstorf.de
Schneider
F
F
Hoppen
H-O
HO
Unger
C
C
Nürnberg
G
G
Becker
F
F
D000818:Animals; D002064:Buserelin / Q000494:pharmacology*; D005260:Female; D005300:Fertility Agents, Female / Q000494:pharmacology*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006736:Horses / Q000097:blood / Q000502:physiology*; D007315:Insemination, Artificial / Q000379:methods / Q000662:veterinary; D007986:Luteinizing Hormone / Q000097:blood*; D003341:Luteolysis / Q000187:drug effects; D011247:Pregnancy; D018873:Pregnancy Rate; D011374:Progesterone / Q000097:blood*; D011897:Random Allocation
D005300:Fertility Agents, Female; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D007986:Luteinizing Hormone; D002064:Buserelin